The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...
Treatment with pembrolizumab plus enfortumab vedotin reduced the risk of disease progression or death by 55% compared with chemotherapy. The Food and Drug Administration (FDA) has accepted for ...
TOKYO and BOTHELL, Wash., Nov. 30, 2023/ PRNewswire/-- Astellas Pharma Inc. and Seagen Inc. today announced that on November 30, 2023 the U.S. Food and Drug Administration accepted for priority review ...
Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...
Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...
Investigators analyzed the immune-modulatory cancer vaccine IO102-IO103 plus pembrolizumab for PFS in patients with untreated advanced melanoma.
Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS). This is an ASCO ...
The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results